The goal of this study was to analyze case study data that suggests the value of adding CA11-19 to monitoring patients at risk of recurrence of colorectal cancer.
- US Capital Global Securities Launches $5 Million Equity Investment in Advanced Medical Device Company
- Two more solid announcements from EDP Biotech
- EDP BioTech’s Eric Mayer back from “InnoSTARS” finals in China
- Seeking Alpha: Augury Investments discusses Exact Sciences and EDP Biotech
- One Knoxville company wins, another competing in InnoSTARS China event